3 Firms Steer Alexion's Deal For VC-Backed Syntimmune
Boston-based biopharmaceutical company Alexion Pharmaceuticals Inc. has agreed to buy venture capital-backed Syntimmune in an up to $1.2 billion deal guided by Foley Hoag LLP, Goodwin Procter LLP and Sullivan &...To view the full article, register now.
Already a subscriber? Click here to view full article